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Abstract 
Background: The current World Health Organization (WHO) classification of nasopharyngeal carcinoma (NPC) con‑
veys little prognostic information. This study aimed to propose an NPC histopathologic classification that can poten‑
tially be used to predict prognosis and treatment response.
Methods: We initially developed a histopathologic classification based on the morphologic traits and cell differentia‑
tion of tumors of 2716 NPC patients who were identified at Sun Yat‑sen University Cancer Center (SYSUCC) (training 
cohort). Then, the proposed classification was applied to 1702 patients (retrospective validation cohort) from hospitals 
outside SYSUCC and 1613 patients (prospective validation cohort) from SYSUCC. The efficacy of radiochemotherapy 
and radiotherapy modalities was compared between the proposed subtypes. We used Cox proportional hazards 
models to estimate hazard ratios (HRs) with 95% confidence intervals (CI) for overall survival (OS).
Results: The 5‑year OS rates for all NPC patients who were diagnosed with epithelial carcinoma (EC; 3708 patients), 
mixed sarcomatoid‑epithelial carcinoma (MSEC; 1247 patients), sarcomatoid carcinoma (SC; 823 patients), and 
squamous cell carcinoma (SCC; 253 patients) were 79.4%, 70.5%, 59.6%, and 42.6%, respectively (P < 0.001). In mul‑
tivariate models, patients with MSEC had a shorter OS than patients with EC (HR = 1.44, 95% CI = 1.27–1.62), SC 
(HR = 2.00, 95% CI = 1.76–2.28), or SCC (HR = 4.23, 95% CI = 3.34–5.38). Radiochemotherapy significantly improved 
survival compared with radiotherapy alone for patients with EC (HR = 0.67, 95% CI = 0.56–0.80), MSEC (HR = 0.58, 
95% CI = 0.49–0.75), and possibly for those with SCC (HR = 0.63; 95% CI = 0.40–0.98), but not for patients with SC 
(HR = 0.97, 95% CI = 0.74–1.28).
Conclusions: The proposed classification offers more information for the prediction of NPC prognosis compared 
with the WHO classification and might be a valuable tool to guide treatment decisions for subtypes that are associ‑
ated with a poor prognosis.
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Background
Nasopharyngeal carcinoma (NPC) is endemic in North 
Africa and Southeast Asia and most notably in South 
China, where the incidence can be as high as 20–40 per 
100,000 persons [1–3]. NPC differs from other head 
and neck cancers with regard to epidemiologic fea-
tures, histopathologic features, treatment strategies, and 
response to therapy [4, 5]. Based on the current World 
Health Organization (WHO) pathologic classification, 
NPCs are grouped into keratinizing squamous cell car-
cinoma (KSCC) and non-keratinizing carcinoma. The 
latter group is further subdivided into non-keratinizing 
differentiated carcinoma (NKDC) and non-keratinizing 
undifferentiated carcinoma (NKUC). However, this sys-
tem is insufficiently informative, as clinical outcomes 
vary substantially among patients with the same clinical 
stage and histopathologic subtype [6–8]. Prognosis does 
not differ significantly between the NKUC and NKDC 
subtypes [8–10]. Pathologists have observed that NPC 
tumor cells have obvious morphologic variations, with 
cells that are small and round, large and round, spindle-
shaped, with or without vesicular nuclei, or mixed round 
and spindle-shaped. Despite this morphologic heteroge-
neity, proposed NPC histopathologic classifications to 
date have not demonstrated clinically relevant improve-
ment in prognostic prediction beyond the WHO clas-
sification [11]. Therefore, clinicians have continued to 
appeal to pathologists to propose an NPC histopatho-
logic classification system that better predicts prog-
nosis and that enables personalized treatment of NPC 
patients.
In advanced NPC, radiochemotherapy (RCT) has been 
extensively investigated and demonstrated to improve 
tumor control and patient survival [12–17]. Two recent 
trials reported no survival benefit of concurrent RCT 
plus adjuvant chemotherapy versus concurrent RCT 
for advanced NPC; in addition, no survival benefit was 
reported with induction chemotherapy plus concurrent 
RCT versus induction chemotherapy plus radiotherapy 
(RT) alone for advanced NPC [16, 18]. Therefore, more 
accurate prognostication is needed to avoid over-treat-
ment and to tailor treatment strategies that are com-
patible with individual risk patterns in a manner that 
improves patients’ survival outcomes.
The primary objective of this large, multi-center study 
was to propose a histopathologic classification system 
for NPC that offers more information on prognosis than 
the WHO classification. A secondary, more exploratory 
objective was to determine whether patients with each 
histopathologic subtype benefit equally in terms of over-
all survival (OS) after RCT versus RT alone.
Methods
Study design
Figure  1 describes the criteria of patient selection and 
exclusion. In detail, the inclusion criteria were as follows: 
the availability of hematoxylin and eosin (H&E) slides 
for review, the availability of follow-up data, no history 
of other treated cancer, and appropriate informed con-
sent from patients. Patients with unknown treatment, 
unknown age or clinical stage, and those who received 
chemotherapy alone were excluded from this study. 
Patients who died from causes unrelated to NPC were 
also excluded. Two clinical staging systems were applied 
due to different geographic areas: patients from main-
land China enrolled before 2006 were staged according 
to the 1992 China staging system [19], whereas patients 
from Hong Kong, Taiwan, Singapore, and Sun Yat-sen 
University Cancer Center (SYSUCC) who were enrolled 
between 2007 and 2011 were staged according to the 
1997 American Joint Committee on Cancer (AJCC) stag-
ing system [20]. The ethics committee or institutional 
review board at each participating center approved the 
study.
Morphologic features of each subtype of the proposed 
classification of NPC
Representative features of each subtype of the proposed 
classification are shown in Fig.  2. NPCs were histologi-
cally classified into the following four subtypes based on 
morphologic features: epithelial carcinoma (EC), sarco-
matoid carcinoma (SC), mixed sarcomatoid-epithelial 
carcinoma (MSEC), and squamous cell carcinoma (SCC). 
Specifically, EC is characterized by small, round tumor 
cells (Fig.  2a, b), large, round cells (Fig.  2c), or a carci-
noma phenotype with vesicular nuclei (Fig.  2d). More 
than 50% of the tumor cells in SC are spindle-shaped, 
fusiform, or are in interlacing bundles (fibrosarcomatous 
pattern) (Fig. 2e–h). Morphologically, MSEC shows nests 
or scattered infiltration of large, round cells in spindle cell 
carcinomatous tissues (Fig. 2i–l). SCC is distinguished by 
tumor cells with a well differentiated keratinizing pheno-
type (Fig. 2m, n) or a poorly or moderately differentiated 
phenotype (Fig. 2o, p).
Inter‑observer reproducibility of slide review
Two experienced pathologists without knowledge of the 
clinical data independently classified all enrolled cases 
from each participating institution according to the 
proposed classification, and simultaneously reclassified 
all cases according to the WHO classification criteria. 
A third pathologist from the institution was consulted 
when the classifications of the first two pathologists 
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conflicted. If the conclusion of the third pathologist was 
different, then the three worked collaboratively to reach 
an agreement. Inter-observer reproducibility of the 
results between the first two pathologists according to 
the new classification was 90.2% (Table 1).
Efficacy of radiotherapy and radiochemotherapy
The patients with advanced NPC who were diagnosed 
between 2001 and 2011 underwent further analysis of 
the therapeutic efficacy of RCT versus RT alone and 
were then stratified by the proposed classification; the 
7565 NPC patients were diagnosed at the involved hospitals between 1995 and 2011
2716 NPC patients were 
enrolled from SYSUCC 
between 1995 and 2005 as a 
training cohort for study on 
relationship between the 
proposed classification and 
prognosis
3893 patients with advanced stage (III + IV) NPC diagnosed between 2001 
and 2011 were enrolled for analysis on therapy efficacy of RT alone (n =
1077) versus RCT (n = 2816)
OS analysis on patients who received different therapy modalities 
stratified by the proposed classification
1218 patients diagnosed before 2001 were 
excluded 
1613 NPC patients were 
enrolled from SYSUCC 
between 2007 and 2011 as a 
prospective validation cohort for 
study on relationship between 
the proposed classification and 
prognosis
1702 NPC patients were enrolled from 
hospitals outside of SYSUCC in 
mainland China (n = 1098), Hong Kong, 
Taiwan, and Singapore (n = 604) 
between 1999 and 2006 as a 
retrospective validation cohort for study 
on relationship between the proposed 
classification and prognosis
194 were excluded for treatment strategies
51 for chemotherapy only
143 for unknown treatment
920 patients with early stage (I + II) NPC
were excluded
Primary analysis
Secondary analysis
1340 were excluded for unavailable data
677 for unavailable histology
609 for incomplete follow-up
33 for unknown clinical stage
7 for unknown age
14 for death unrelated with NPC 
A total of 6031 patients were eventually enrolled 
Fig. 1 Flowchart of the study design shows the inclusion and exclusions of nasopharyngeal carcinoma (NPC) patients with different therapeutic 
modalities stratified by the proposed classification. SYSUCC Sun Yat‑sen University Cancer Center, OS overall survival, RT radiotherapy, RCT radio‑
chemotherapy
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patients who were diagnosed before January 1, 2001, and 
those with early-stage disease were excluded to reduce 
variation in treatment protocols (Fig. 1). All patients with 
advanced NPC underwent standard curative RT, and 
some received additional chemotherapy. Patients in both 
groups received RT according to the policy at each center. 
The treatment protocol used at the largest contributing 
center was reported previously [21]. Generally, a regi-
men that consisted of 2 Gy per fraction, with 5 daily frac-
tions per week, was used. A minimum dose of 60 Gy was 
given to gross tumor targets, while 50  Gy was given at 
sites of local infiltration and bilateral cervical lymphatic 
metastases. Patients who received RCT were adminis-
tered neoadjuvant, concurrent, or adjuvant cisplatin (30–
40 mg/m2 every week or 100 mg/m2 every 3 weeks) plus 
5-fluorouracil (750 mg/m2 per day, days 1–5).
Statistical analysis
Probabilities of OS were estimated using the Kaplan–
Meier method, and the log-rank test was used to detect 
differences among groups. We assessed the associa-
tions between clinical characteristics and subtypes of 
NPC classified according to the proposed classification 
using Student’s t test and the Chi square test. To test if 
Fig. 2 Representative morphologic traits of tumors according to the proposed classification of NPC (H&E, ×400). The epithelial carcinoma (EC) 
subtype shows small, round cells with cellular stratification and a pavement‑like appearance, a low nucleus:cytoplasm ratio, chromatin‑rich nuclei 
(a), and non‑prominent nucleoli (b); or syncytial‑appearing large tumor cells with indistinct cell borders, round‑to‑oval vesicular nuclei, and large 
central nucleoli (c); a round shape with vesicular nuclei and prominent nucleoli accounting for more than 75% of tumor cells (d). The sarcomatoid 
carcinoma (SC) subtype features irregular small cells, large hyperchromatic cells, or both, or uniformly medium‑sized spindle cells (e), together with 
nucleoli that are less prominent than those in the syncytial‑appearing cells (f), dark, smudged nuclei and a dense amphophilic (g), or eosinophilic 
cytoplasm (h). The mixed sarcomatoid‑epithelial carcinoma (MSEC) subtype is characterized by large, round cell nests (i) or scattered infiltration of 
large, round cells in the spindle cell carcinomatous tissue (j); no obvious boundaries were observed between the tumor and interstitial lymphoid 
tissue (k) or in the stromal portion that contained cells with eosinophilic cytoplasm (l). The squamous cell carcinoma (SCC) subtype shows well 
differentiated keratinizing SCC with a large number of whorls (m) and keratin (n), or poorly or moderately differentiated SCC with some individual 
keratinized spine cells (o) and a small number of basal‑like cells (p)
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the proposed classification was an independent prognos-
tic factor of OS, we adjusted for age, sex, clinical stage, 
therapeutic modality, and the WHO classification and 
used multivariate Cox proportional hazards regression 
models to estimate hazard ratios (HRs) with 95% con-
fidence intervals (CI). The heterogeneity according to 
clinical stage in the association between histopathologic 
classification and OS was examined by the inclusion of an 
interaction term between stage and histology and by the 
stratification of models by stage at diagnosis. The patients 
were followed every 6  months, and a 5-year follow-up 
Table 1 Inter-observer reproducibility between  two 
pathologists based on the new nasopharyngeal carcinoma 
(NPC) histopathologic classification, stratified by  area 
of case origin
In all, 4642 out of the 7565 patients in the initial database were assessed for the 
initial calculation of reproducibility
Case origin Consistent 
(cases)
Inconsistent 
(cases)
Reproducibility 
(%)
Sun Yat‑sen University 
Cancer Center  
(SYSUCC)
3067 325 90.3
Other hospitals in  
mainland China
582 53 91.7
Hong Kong, Taiwan, 
Singapore
535 77 87.4
Total 4187 455 90.2
Table 2 Distribution of  clinical centers where  the 6031 
enrolled nasopharyngeal carcinoma patients received a 
biopsy and therapy
Center for biopsy Center for therapy Number 
of cases
Department of Pathology, Sun 
Yat‑sen University Cancer Center 
(SYSUCC), Guangzhou, Guang‑
dong, China
Department of Radiation 
Oncology, SYSUCC
4329
Department of Pathology, multi‑
ple local centers in Guangdong, 
China
Department of Radiation 
Oncology, SYSUCC
504
Department of Pathology, 
Guangxi Medical University Can‑
cer Center, Nanning, Guangxi, 
China
Department of Radiation 
Oncology, Guangxi 
Medical University 
Cancer Center
204
Department of Pathology, Cancer 
Institute and Hospital, Chinese 
Academy of Medical Sciences 
(CAMS), Beijing, China
Department of Radiation 
Oncology, Cancer 
Hospital, CAMS
100
Department of Pathology, The 
Affiliated Hospital of Bengbu 
Medical College, Bengbu, Anhui, 
China
Department of Radiation 
Oncology, The Affiliated 
Hospital of Bengbu 
Medical College
113
Department of Pathology, Hunan 
Provincial Cancer Hospital, 
Changsha, Hunan, China
Department of Radiation 
Oncology, Hunan Pro‑
vincial Cancer Hospital
130
Department of Pathology, Fujian 
Provincial Tumor Hospital, 
Fuzhou, Fujian, China
Department of Radiation 
Oncology, Fujian Provin‑
cial Tumor Hospital
47
Department of Anatomical and 
Cellular Pathology, Faculty of 
Medicine, the Chinese University 
of Hong Kong (CUHK), Hong 
Kong, China
Department of Clinical 
Oncology, CUHK
207
Department of Pathology, 
National Taiwan University 
Hospital, Taipei, Taiwan
Department of Otolaryn‑
gology, National Taiwan 
University Hospital
211
Department of Pathology, 
Singapore General Hospital, 
Singapore, Singapore
Department of Radiation 
Oncology, National Can‑
cer Center, Singapore
186
Table 3 Clinical characteristics of  NPC patients in  the 
training, retrospective validation, and prospective valida-
tion cohorts
NPC nasopharyngeal carcinoma, EC epithelial carcinoma, SC sarcomatoid 
carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SCC squamous 
cell carcinoma, WHO World Health Organization, NKUC non-keratinizing 
undifferentiated carcinoma, NKDC non-keratinizing differentiated carcinoma, 
KSCC keratinizing squamous cell carcinoma, OS overall survival, CI confidence 
interval
Characteristic Training  
cohort
Retrospective 
validation  
cohort
Prospective 
validation 
cohort
Total (cases) 2716 1702 1613
Age (years)
 Median (range) 46 (10–86) 47 (10–90) 47 (11–83)
Follow‑up time (months)
 Median (range) 68 (1–120) 68 (1–120) 41 (1–91)
Sex [cases (%)]
 Female 658 (24.2) 501 (29.4) 404 (25.1)
 Male 2058 (75.8) 1201 (70.6) 1209 (74.9)
Clinical stage [cases (%)]
 I 75 (2.8) 67 (4.0) 35 (2.2)
 II 549 (20.2) 388 (22.8) 104 (6.5)
 III 1272 (46.8) 695 (40.8) 458 (28.4)
 IV 820 (30.2) 552 (32.4) 1016 (62.9)
Therapeutic modality [cases (%)]
 Radiotherapy 
alone
1592 (58.6) 928 (54.5) 220 (13.6)
 Radiochemo‑
therapy
1124 (41.4) 774 (45.5) 1393 (86.4)
Proposed classification [cases (%)]
 EC 1520 (55.9) 987 (58.0) 1202 (74.5)
 MSEC 598 (22.0) 420 (24.7) 229 (14.2)
 SC 489 (18.0) 198 (11.6) 135 (8.4)
 SCC 109 (4.1) 97 (5.7) 47 (2.9)
WHO classification [case (%)]
 NKUC 2261 (83.2) 1425 (83.8) 1185 (73.5)
 NKDC 409 (15.1) 227 (13.3) 414 (25.7)
 KSCC 46 (1.7) 50 (2.9) 14 (0.8)
OS rate (%)
 5‑year (95% CI) 68.7 (66.9–70.5) 73.3 (71.1–75.4) 83.5 (81.1–85.6)
Page 6 of 16Wang et al. Chin J Cancer  (2016) 35:41 
was achieved for 75.9% (4583/6031) of the NPC patients. 
However, enrollment in the prospective validation cohort 
continued until as recently as 2011, and follow-up data 
were recorded until April 2, 2015; therefore, the 5-year 
follow-up rate was 38.5% in this cohort. We calculated 
the OS from the date of diagnosis until the date of death 
of NPC or the last date of follow-up. All statistical tests 
were two-sided, and a P value of less than 0.05 was con-
sidered statistically significant. All statistical analyses 
were performed with Stata software (version 13, the Uni-
versity of California, Los Angeles, CA, USA).
Results
Patient characteristics
This study enrolled 6031 patients with newly diagnosed, 
histologically confirmed, previously untreated NPC: 4329 
were enrolled from SYSUCC in Guangzhou, China, 604 
from Hong Kong, Taiwan, and Singapore, and 1098 from 
other institutions in mainland China (Table  2). Table  3 
summarizes the demographic and clinical characteristics 
of NPC patients in the training, retrospective validation, 
and prospective validation cohorts, who were followed up 
for a median of 68, 68, and 41 months, respectively. NPC 
Fig. 3 Kaplan‑Meier curves of OS according to the proposed classification, the World Health Organization (WHO) classification, and clinical stage 
in NPC patients from the training (n = 2716), retrospective validation (n = 1702), and prospective validation cohorts (n = 1613), respectively. OS 
curves of patients classified with the proposed classification in the training (a), retrospective validation (b), and prospective validation cohorts (c). 
OS curves of patients classified with WHO classification in the training (d), retrospective validation (e), and prospective validation cohorts (f). OS 
curves of patients classified with clinical stage in the training (g), retrospective validation (h), and prospective validation cohorts (i). The log‑rank test 
was used to estimate P values. *The training cohort was classified by the 1992 China staging system; the retrospective validation cohort was classi‑
fied by the 1992 China staging system or the 1997 American Joint Committee on Cancer (AJCC) staging system; the prospective validation cohort 
was classified by the 1997 AJCC staging system
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patients in the training cohort (n = 2716) from SYSUCC 
and the retrospective validation cohort from other hos-
pitals in mainland China (n = 1098) were staged accord-
ing to the 1992 China staging system. Patients from Hong 
Kong, Taiwan, and Singapore in the retrospective valida-
tion cohort (n = 604) as well as patients from SYSUCC in 
the prospective validation cohort (n = 1613) were staged 
according to the 1997 AJCC staging system (Fig. 1).
The proposed classification of NPC and patient survival
The 5-year OS rates in the training, retrospective vali-
dation, and prospective validation cohorts were 68.7%, 
73.3%, and 83.5%, respectively (Table 3). Figure 3 displays 
that the differences in OS curves were significant for 
patients classified with the proposed classification system 
(P < 0.001) as well as for patients classified with clinical 
stage (P < 0.001) in each cohort. However, no difference 
was observed between the NKUC and NKDC subtypes, 
although the difference in OS of patients stratified by 
WHO classification remained significant in the training 
cohort (P  =  0.003) and retrospective validation cohort 
(P = 0.021).
Because the association between the proposed classi-
fication and the 5-year OS was similar across the three 
cohorts, we combined all 6031 NPC patients for subse-
quent analysis. In all NPC patients, the 5-year OS rates 
for the EC, MSEC, SC, and SCC subtypes were 79.4%, 
70.5%, 59.6%, and 42.6%, respectively (Table 4). The dif-
ference in the 5-year OS rate was 8.9% between the most 
common subtypes (EC and MSEC), which together com-
prised 82.2% of all patients; the difference was 19.8% 
between the EC and SC subtypes, which together com-
prised 75.1% of all patients; the difference was 17.0% 
between the poor-prognosis subtypes SC and SCC, 
which together comprised 17.8% of all patients in the 
study. These significant differences indicate that the 
Table 4 Cox proportional regression analysis of the associations between patient characteristics and OS in all 6031 NPC 
patients
OS overall survival, NPC nasopharyngeal carcinoma, HR hazard ratio, CI confidence interval, EC epithelial carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SC 
sarcomatoid carcinoma, SCC squamous cell carcinoma, WHO World Health Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC non-keratinizing 
differentiated carcinoma, KSCC keratinizing squamous cell carcinoma
a  All models were adjusted for the proposed classification, age, sex, therapeutic modality, clinical stage, and WHO classification
Characteristic Patients  
[cases (%)]
OS rate (%) Unadjusted  
HR
95% CI P value Adjusted  
HRa
95% CI P value
5‑year 95% CI
Proposed classification
 EC 3708 (61.5) 79.4 78.1–80.8 1.00 Reference 1.00 Reference
 MSEC 1247 (20.7) 70.5 67.7–73.0 1.48 1.32–1.67 <0.001 1.44 1.27–1.62 <0.001
 SC 823 (13.6) 59.6 55.9–63.1 2.16 1.90–2.44 <0.001 2.00 1.76–2.28 <0.001
 SCC 253 (4.2) 42.6 35.8–49.3 3.56 2.96–4.28 <0.001 4.23 3.34–5.38 <0.001
Age
 ≤47 years 3163 (52.5) 77.8 76.3–79.3 1.00 Reference 1.00 Reference
 >47 years 2868 (47.5) 68.4 66.6–70.2 1.54 1.40–1.70 <0.001 1.50 1.36–1.65 <0.001
Sex
 Male 4468 (74.1) 71.7 70.3–73.1 1.00 Reference 1.00 Reference
 Female 1563 (25.9) 78.1 75.8–80.2 0.73 0.65–0.81 <0.001 0.76 0.68–0.86 <0.001
Therapeutic modality
 Radiotherapy alone 2739 (45.4) 71.4 69.6–73.1 1.00 Reference 1.00 Reference
 Radiochemotherapy 3292 (54.6) 75.2 73.4–76.8 0.88 0.79–0.97 0.009 0.65 0.59–0.72 <0.001
Clinical stage
 I 177 (2.9) 92.4 87.1–95.5 1.00 Reference 1.00 Reference
 II 1041 (17.3) 85.6 83.2–87.6 2.20 1.27–3.79 0.004 2.25 1.3–3.89 0.003
 III 2424 (40.2) 74.3 72.4–76.0 4.17 2.46–7.08 <0.001 4.70 2.76–7.98 <0.001
 IV 2389 (39.6) 64.9 62.7–67.0 5.77 3.40–9.78 <0.001 6.96 4.09–11.85 <0.001
WHO classification
 NKUC 4871 (80.8) 73.8 72.5–75.1 1.00 Reference 1.00 Reference
 NKDC 1050 (17.4) 73.2 70.1–75.9 1.02 0.90–1.16 0.729 1.00 0.87–1.16 0.980
 KSCC 110 (1.8) 57.5 47.0–66.6 1.85 1.38–2.47 <0.001 0.51 0.35–0.74 <0.001
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Fig. 4 Kaplan‑Meier survival estimates for NPC patients according to two different staging systems. In all, 3814 (63.2%) NPC patients from mainland 
China were diagnosed before 2006 and were staged according to the 1992 China staging system, whereas 2217 (36.8%) from Hong Kong, Taiwan, 
Singapore, and SYSUCC (in mainland China) were diagnosed between 2007 and 2011 and were staged according to the 1997 AJCC staging system. 
The 5‑year OS rate was 69.2% (95% CI = 67.7%–70.6%) for patients classified by the 1992 China staging system (a) and 82.2% (95% CI = 80.3%–
83.9%) for patients classified by the 1997 AJCC staging system (b). The OS differed significantly by clinical stage according to the 1992 China staging 
system (P < 0.001, c) and the 1997 AJCC staging system (P < 0.001, d). The log‑rank test was used to calculate P values
Fig. 5 Associations between clinical stage and the proposed histopathologic classification in all NPC patients. The proportions of EC cases are 
71.8%, 63.3%, 61.1%, and 60.4% in patients with stages I, II, III, and IV NPC (the 1992 China and 1997 AJCC staging systems combined), respectively, 
whereas those of SC cases are 9.6%, 11.8%, 13.7%, and 14.6%, respectively. The proportion of SC increased with advanced stage, whereas the pro‑
portion of EC decreased with more advanced stage (Chi square test, P = 0.001)
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proposed classification can distinguish the prognosis of 
NPC patients. By contrast, according to the WHO clas-
sification, a difference of only 0.6% was detected between 
the two most common subtypes (NKUC and NKDC), 
which together comprised 98.2% of all patients. NKUC 
cases were reclassified by the proposed classification 
primarily as EC (60.0%) and as MSEC (24.2%), whereas 
NKDC cases were reclassified primarily as EC (81.3%) 
(Chi square test, P < 0.001).
The association between clinical stage and the proposed 
NPC classification
Different clinical staging systems were adopted in this 
study. The 5-year OS rate was 69.2% (95% CI = 67.7%–
70.6%) for patients who were classified according to 
the 1992 China staging system (Fig.  4a) and was 82.2% 
(95% CI  =  80.3%–83.9%) for patients who were classi-
fied according to the 1997 AJCC staging system (Fig. 4b). 
The association between the proposed classification 
and clinical stage was statistically significant when 
both staging systems were combined (Chi square test, 
P < 0.001; Fig. 5). After stratification by the combination 
of both clinical staging systems, the proposed classifica-
tion still remained a significant predictor of prognosis in 
all NPC patients (Fig. 6). In the three cohorts that were 
examined separately, the proposed classification retained 
significance in the prediction of prognosis, especially 
in NPC patients with stages III and IV cancers, who 
accounted for approximately 80% of the enrolled patients 
(Fig.  7). This remained true irrespective of whether the 
clinical stage was determined according to the 1992 
China staging system or the 1997 AJCC staging system 
(Fig. 8).
Multivariate analysis of OS according to the proposed 
classification
The proportional hazards assumption for each covari-
ate was tested by graphical methods, and no significant 
violations were found. In the univariate analyses of OS 
for all NPC patients, the subtypes of MSEC, SC, and 
Fig. 6 Kaplan‑Meier survival estimates for NPC patients at different clinical stages (the 1992 China and 1997 AJCC staging systems combined) strati‑
fied by subtypes according to the proposed histopathologic classification. The OS differed significantly by the proposed classification for patients 
with stage I (P = 0.015, a), II (P < 0.001, b), III (P < 0.001, c), or IV disease (P < 0.001, d). The log‑rank test was used to calculate P values
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SCC, older age, male sex, RT alone, and advanced clini-
cal stage were associated with significantly shorter OS 
(Table 4). In the multivariate analysis, the proposed clas-
sification independently predicted OS even after adjust-
ments for age, sex, therapeutic modality, tumor stage, 
and WHO classification. Compared with EC, the HR 
was 1.44 (95% CI = 1.27–162, P < 0.001) for MSEC, 2.00 
(95% CI =  1.76–2.28, P  <  0.001) for SC, and 4.23 (95% 
CI  =  3.34–5.38, P  <  0.001) for SCC (Table  4). After 
multivariate adjustment, the SC subtype predicted a 
higher risk of death compared with the MSEC subtype 
(HR =  1.40, 95% CI =  1.21–1.61, P < 0.001); moreover, 
SCC was associated with a higher risk of death compared 
with SC (HR = 2.11, 95% CI = 1.63–2.75, P < 0.001) (data 
not shown).
Therapeutic efficacy of RCT versus RT alone
Overall, 3893 patients with advanced NPC who were 
diagnosed between 2001 and 2011 were stratified by the 
proposed classification and underwent further analy-
sis to determine the therapeutic efficacy of RCT versus 
RT alone (Fig. 1). The baseline demographic and clinical 
characteristics of patients with advanced NPC who were 
treated with RCT (n = 2816) or RT alone (n = 1077) are 
shown in Table  5. The 5-year OS rates of patients with 
advanced NPC differed significantly between the RCT 
and RT alone groups (75.6% vs. 64.8%, P < 0.001). RCT 
prolonged OS as compared with RT alone for patients 
with the EC subtype (HR  =  0.67, 95% CI  =  0.56–0.80, 
P  <  0.001; Fig.  9a) and the MSEC subtype (HR =  0.58, 
95% CI  =  0.49–0.75, P  <  0.001; Fig.  9b), but not for 
Fig. 7 Kaplan‑Meier survival estimates for NPC patients at different clinical stages in three separate cohorts stratified by subtypes according to 
the proposed classification. OS curves of NPC patients stratified by subtypes according to the proposed classification with stage I (P = 0.005, a; 
(P = 0.063, b; c), II (P = 0.057, d; P = 0.030, e; and P < 0.001, f), III (P < 0.001, g and h; P = 0.041, i), and IV disease (P < 0.001, j, k, and l) in the training, 
retrospective validation, and prospective validation cohorts, respectively. The log‑rank test was used to calculate P values. *No test possible because 
there were no failures
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Fig. 8 Kaplan‑Meier survival estimates for NPC patients at different clinical stages according to two staging systems and stratified by subtypes 
according to the proposed classification. The OS differed significantly according to subtype of the proposed classification for patients at differ‑
ent clinical stages classified according to the 1992 China staging system (P = 0.031, a; P = 0.002, c; P < 0.001, e and g) and the 1997 AJCC staging 
system (all P < 0.001, d, f, and h), respectively. The log‑rank test was used to calculate P values
Page 12 of 16Wang et al. Chin J Cancer  (2016) 35:41 
patients with the SC subtype (HR = 0.97, 95% CI = 0.74–
1.28, P = 0.826; Fig. 9c). However, this was also likely the 
case for those with the SCC subtype (HR  =  0.63, 95% 
CI = 0.40–0.98, P = 0.048; Fig. 9d). A multivariate Cox 
analysis showed that after adjustment for age, sex, clini-
cal stage, and the WHO classification, both therapeutic 
modality and the proposed classification were signifi-
cant predictors of the survival of advanced NPC patients 
(Table 6).
Due to the unbalanced distribution of clinical stages III 
and IV between the RCT and RT alone groups (Table 5), 
we repeated this analysis after the included cases were 
restricted to either stage III or stage IV NPC. Consistent 
with the results for all advanced NPC patients, significant 
differences in the 5-year OS rates were observed between 
patients who were treated with RCT and RT alone within 
the subtypes of EC and MSEC after the cases were 
restricted to either stage III or stage IV cancers (data not 
shown).
Discussion
Prognostic evaluation is pivotal for making decisions 
concerning appropriate treatment delivery. In our pre-
sent study, we developed an NPC histopathologic classifi-
cation that can distinguish among the different subtypes 
with clinically and statistically significant differences in 
the 5-year OS rate, even after multivariate adjustment for 
or stratification by TNM stage. Compared with the train-
ing and retrospective validation cohorts, the estimated 
5-year OS rate was most likely higher in the prospective 
validation cohort due to the more widespread delivery 
of RCT to NPC patients seen between 2007 and 2011 at 
SYSUCC. An additional explanation for the higher 5-year 
OS rate in this cohort (83.5% vs. 68.7% and 73.3% in the 
other two cohorts) is that it also had the shortest median 
follow-up time (41 vs. 68 and 68  months in the other 
cohorts), which was due partly to the more recent diag-
nosis of these patients.
Considerable controversy surrounds the WHO classi-
fication and its prognostic value [22]. The WHO KSCC 
subtype accounts for one-third to one-half of all NPC 
cases in western populations, and this subtype is asso-
ciated with a worse prognosis compared with non-
keratinizing carcinoma [23, 24]. However, studies have 
consistently failed to show that the distinction between 
the WHO NKDC and NKUC subtypes has any clinical 
relevance [6–8]. These two subtypes comprise more than 
95% of NPCs in endemic areas, including in our study 
population [4, 25].
RCT has consistently produced a survival benefit com-
pared with RT alone, and 5-year OS rates of approxi-
mately 70% have been achieved by RCT in patients with 
stages III and IV NPC [12–15, 18, 26–30]. Lewis et  al. 
[31] reported that 10.9% of patients received inadequate 
adjuvant therapy and 4.4% received inadequate radio-
therapy based on the US National Comprehensive Can-
cer Network head-and-neck guidelines for recurrent or 
residual head-and-neck cancer. Exploratory analyses in 
our study indicated that compared with RT alone, RCT 
may improve outcomes in patients with advanced disease 
for the EC and MSEC subtypes, and possibly for the SCC 
subtype, but no evidence of an effect for the SC subtype 
was found. The worse prognosis of patients with the SC 
and SCC subtypes suggests that the current therapeutic 
methods are insufficient for these disease subtypes. Our 
results indicate that the proposed classification system 
may enable a more tailored approach for optimal clini-
cal treatment decisions, especially for the SC and SCC 
subtypes, in which patients may need aggressive thera-
pies such as high-dose irradiation, neoadjuvant and/or 
Table 5 Clinical characteristics of  3893 patients 
with advanced NPC who were treated with different thera-
peutic modalities
NPC nasopharyngeal carcinoma, RT radiotherapy, RCT radiochemotherapy, 
EC epithelial carcinoma, MSEC mixed sarcomatoid-epithelial carcinoma, SC 
sarcomatoid carcinoma, SCC squamous cell carcinoma, WHO World Health 
Organization, NKUC non-keratinizing undifferentiated carcinoma, NKDC 
non-keratinizing differentiated carcinoma, KSCC keratinizing squamous cell 
carcinoma, OS overall survival, CI confidence interval
* Chi square test
† Student’s t test
§ Log-rank test
Characteristic RT alone RCT P value
Total (cases) 1077 2816
Age (years) <0.001†
 Median (range) 48 (11–90) 47 (10–85)
Follow‑up time (months) <0.001†
 Median (range) 60 (2–120) 52 (2–120)
Sex [cases (%)] 0.120*
 Male 785 (72.9) 2120 (75.3)
 Female 292 (27.1) 696 (24.7)
Clinical stage [cases (%)] <0.001*
 III 685 (63.6) 1144 (40.6)
 IV 392 (36.4) 1672 (59.4)
Proposed classification [cases (%)] <0.001*
 EC 622 (57.8) 1845 (65.5)
 MSEC 228 (21.2) 531 (18.9)
 SC 178 (16.5) 320 (11.3)
 SCC 49 (4.5) 120 (4.3)
WHO classification [cases (%)] <0.001*
 NKUC 889 (82.5) 2215 (78.6)
 NKDC 160 (14.9) 560 (20.0)
 KSCC 28 (2.6) 41 (1.4)
OS rate (%) <0.001§
 5‑year (95% CI) 64.8 (61.7–67.6) 75.6 (73.8–77.3)
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adjuvant chemotherapy, surgery, and molecularly tar-
geted therapy to yield additional therapeutic gains. The 
efficacy of such therapies will require randomized clinical 
trials that stratify patients by histopathologic subtypes.
In the present study, the MRI and CT information of 
some patients are unavailable, particularly for the train-
ing cohort. The 1997 AJCC staging system is not applica-
ble for these patients. Therefore, the 1992 China staging 
system was used. Our data clearly showed that differ-
ent staging systems consistently predict the prognosis 
of NPC patients. Differences between these two staging 
systems mainly involve the classification of the borders 
of the tumor and lymph nodes in advanced disease [32]. 
Furthermore, Hong et  al. [33] reported a high degree of 
similarity (72.1%) between the 1992 China staging system 
and the 5th edition of the AJCC staging system for NPC; 
the latter was then developed into the 6th AJCC system 
with minimal modification. In another study that com-
pared the 5, 6, and 7th editions of the AJCC staging sys-
tem in a total of 985 NPC patients, a minimal magnitude 
of improvement in prognostication was found [34]. There-
fore, the 1992 China and 1997 AJCC staging systems were 
both acceptable for the prediction of prognosis.
A limitation to consider is in terms of generalizability 
because all included patients were from NPC-endemic 
areas in East Asia. The replication of our results in non-
Asian patients needs to be confirmed for the use in clin-
ics worldwide. We had incomplete follow-up data for 24% 
of the cohort, which raises the possibility of selection 
bias; however, differential follow-up based on histopatho-
logic subtype was unlikely. The distribution of clinical 
stages differed between the RCT and RT alone groups, in 
which the patients were not randomized. Therefore, the 
efficacy of therapeutic strategies in patients with differ-
ent histopathologic subtypes should be explored in future 
randomized clinical trials with complete follow-up. We 
cannot exclude the possibility that shorter survival in 
some groups is due to comorbidity, performance status, 
or some other unmeasured prognostic factors, rather 
than histopathologic subtype. However, no prior studies 
Fig. 9 Kaplan‑Meier survival estimates for the 3893 advanced NPC patients with different proposed subtypes who underwent radiochemotherapy 
(RCT) or radiotherapy (RT) alone. RCT significantly improved survival compared to RT alone for patients with EC (P < 0.001, a) and MSEC (P < 0.001, 
b), but not for patients with SC (P = 0.826, c); this was also likely the case for those with SCC (P = 0.048, d). The log‑rank test was used to compute P 
values. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed for each type (RCT versus RT alone)
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have demonstrated an association between histopatho-
logic features and comorbidity or performance status, 
which indicates that they are unlikely to be strong con-
founders. Finally, complex gene networks may be the 
underlying mechanisms for the morphologic traits; thus, 
genomic analyses are warranted for further investigation 
and verification to elucidate the molecular basis for the 
proposed classification.
In conclusion, this multi-center study proposes an 
NPC histopathologic classification system that can sig-
nificantly distinguish prognosis beyond clinical stage 
among non-squamous subtypes of NPC. The finding that 
RCT improves survival over RT alone in patients with 
advanced EC and MSEC suggests that more attention 
should be paid to the improvement of clinical outcomes 
for the SC and SCC subtypes, which are associated with a 
worse prognosis.
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